Psoriatic Arthritis Treatment Market Size, Industry Trends | Analysis 2024-2032

Comments · 13 Views

The global Psoriatic Arthritis (PsA) treatment market size reached US$ 10.8 billion in 2023. The market to reach US$ 20.5 billion in 2032, exhibiting a growth rate (CAGR) of 7.4% during 2024-2032.

The Reports and Insights, a leading market research company, has recently releases report titled “Psoriatic Arthritis (PsA) Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032.” The study provides a detailed analysis of the industry, including the global Psoriatic Arthritis (PsA) Treatment Market Trends, size, share, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Report Highlights:

How big is the Psoriatic Arthritis (PsA) Treatment Market?

The global Psoriatic Arthritis (PsA) treatment market size reached US$ 10.8 billion in 2023. The market to reach US$ 20.5 billion in 2032, exhibiting a growth rate (CAGR) of 7.4% during 2024-2032.

What are Psoriatic Arthritis (PsA) Treatment Market?

Treatment for Psoriatic Arthritis (PsA) involves addressing both joint inflammation and the skin symptoms of psoriasis, as the condition affects both aspects. Typically, a combination of medications like nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), biologics, and corticosteroids is used to reduce inflammation, pain, and swelling in the joints. Additionally, topical treatments, phototherapy, and lifestyle changes such as exercise and weight management are often recommended to manage skin symptoms and enhance the overall quality of life for individuals with PsA.

Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/2231

What are the growth prospects and trends in the Psoriatic Arthritis (PsA) Treatment Market industry?

The psoriatic arthritis (PsA) treatment market growth is driven by various factors. The market for treating Psoriatic Arthritis (PsA) is growing significantly due to the increasing global prevalence of the condition. This market offers a variety of treatment choices, such as nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), biologics, and corticosteroids, all aimed at managing joint inflammation and skin symptoms. Furthermore, new therapies and biologics are emerging, expanding the range of treatments available to PsA patients. Increased awareness of PsA and its treatment options, along with rising healthcare spending in developing regions, are also contributing to the market's growth. Hence, all these factors contribute to psoriatic arthritis (PsA) treatment market growth.

What is included in market segmentation?

The report has segmented the market into the following categories:

By Treatment Type

  • Medications
  • NSAIDs (Nonsteroidal Anti-Inflammatory Drugs)
  • DMARDs (Disease-Modifying Antirheumatic Drugs)
  • Biologics
  • Physical Therapy
  • Lifestyle Modifications

By Mode of Administration

  • Oral
  • Injectable
  • Topical

By Patient Type

  • Newly Diagnosed
  • Moderate to Severe Psoriatic Arthritis
  • Refractory or Resistant Cases

By End User

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Homecare Settings

North America

  • United States
  • Canada

Europe

  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Russia
  • Poland
  • Benelux
  • Nordic
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • South Korea
  • ASEAN
  • Australia & New Zealand
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Argentina

Middle East & Africa

  • Saudi Arabia
  • South Africa
  • United Arab Emirates
  • Israel
  • Rest of MEA

Who are the key players operating in the industry?

The report covers the major market players including:

  • AbbVie Inc.
  • Amgen Inc.
  • Johnson & Johnson
  • Pfizer Inc.
  • Eli Lilly and Company
  • Novartis International AG
  • Bristol Myers Squibb Company
  • UCB S.A.
  • Celgene Corporation (acquired by Bristol Myers Squibb)
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc.
  • Gilead Sciences, Inc.
  • Roche Holding AG
  • Sanofi S.A.

Discover more: https://www.reportsandinsights.com/report/psoriatic-arthritis-psa-treatment-market

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact Us:

Reports and Insights Business Research Pvt. Ltd.
1820 Avenue M, Brooklyn, NY, 11230, United States
Contact No: +1-(347)-748-1518
Email: sales@reportsandinsights.com
Website: https://www.reportsandinsights.com/
Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/
Follow us on twitter: https://twitter.com/ReportsandInsi1

disclaimer
Comments